Amphastar Pharmaceuticals, Inc. (AMPH)

↓ Download CSV

CIK 0001297184 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

In fiscal 2025, Amphastar Pharmaceuticals, Inc. reported revenue of $719.89M, down 1.7% from the prior year. The company was profitable, with a net margin of 13.6% and a gross margin of 49.5%. It held $1.63B in total assets against $840.49M in total liabilities.

Key ratios (FY2025)

49.5%
Gross margin
19.5%
Operating margin
13.6%
Net margin
12.4%
Return on equity
-1.7%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$719.89M$731.97M$644.39M$498.99M$437.77M$349.85M$322.36M$294.67M$240.18M$255.16M
Cost of Revenue$363.83M$358.11M$293.27M$250.13M$238.03M$206.51M$190.43M$187.68M$149.67M$150.97M
Gross Profit$356.06M$373.86M$351.12M$248.86M$199.74M$143.34M$131.92M$106.98M$90.51M$104.20M
Operating Income$140.40M$205.42M$196.99M$107.50M$69.89M$10.95M-$39.0K-$8.62M-$1.27M$15.38M
Net Income$98.09M$159.52M$137.54M$91.39M$62.12M$1.40M$48.94M-$5.74M$3.65M$9.82M
EPS (Diluted)$2.03$3.06$2.60$1.74$1.25$0.03$0.98$-0.12$0.08$0.21
Total Assets$1.63B$1.58B$1.51B$741.99M$671.53M$631.24M$586.97M$513.56M$451.07M$427.74M
Total Liabilities$840.49M$845.17M$873.49M$213.33M$226.01M$182.51M$159.44M$149.20M$117.34M$98.48M
Shareholders' Equity$788.80M$732.30M$639.42M$528.66M$445.52M$448.72M$427.53M$364.36M$333.74M$326.52M
Cash & Equivalents$170.18M$151.61M$144.30M$156.10M$126.35M$92.64M$73.69M$86.34M$65.59M$72.35M
Operating Cash Flow$156.12M$213.39M$183.50M$89.18M$97.99M$57.27M$41.76M$38.19M$39.21M$38.56M
Capital Expenditures$34.88M$41.04M$38.17M$24.03M$27.46M$33.85M$41.55M$46.81M$35.10M$21.38M
Shares Outstanding48.22M52.06M53.00M52.43M49.78M49.12M49.91M46.40M48.37M47.50M